MX2024001935A - Metodos y composiciones para tratar el cancer. - Google Patents
Metodos y composiciones para tratar el cancer.Info
- Publication number
- MX2024001935A MX2024001935A MX2024001935A MX2024001935A MX2024001935A MX 2024001935 A MX2024001935 A MX 2024001935A MX 2024001935 A MX2024001935 A MX 2024001935A MX 2024001935 A MX2024001935 A MX 2024001935A MX 2024001935 A MX2024001935 A MX 2024001935A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treating cancer
- scc
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 3
- 201000000744 recessive dystrophic epidermolysis bullosa Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232409P | 2021-08-12 | 2021-08-12 | |
| PCT/US2022/040092 WO2023018891A1 (en) | 2021-08-12 | 2022-08-11 | Methods and compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001935A true MX2024001935A (es) | 2024-03-21 |
Family
ID=85200519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001935A MX2024001935A (es) | 2021-08-12 | 2022-08-11 | Metodos y composiciones para tratar el cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240299326A1 (https=) |
| EP (1) | EP4384498A1 (https=) |
| JP (1) | JP2024531238A (https=) |
| CN (1) | CN118076583A (https=) |
| AU (1) | AU2022326485A1 (https=) |
| CA (1) | CA3228644A1 (https=) |
| CO (1) | CO2024002786A2 (https=) |
| GB (1) | GB2628229A (https=) |
| IL (1) | IL310759A (https=) |
| MX (1) | MX2024001935A (https=) |
| WO (1) | WO2023018891A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5156389B2 (ja) * | 2005-01-05 | 2013-03-06 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 薬剤耐性増殖性疾患の治療剤 |
| WO2014089483A1 (en) * | 2012-12-07 | 2014-06-12 | Onconova Therapeutics, Inc. | Methods and compositions for treatment of cancer |
| JP2018530590A (ja) * | 2015-10-14 | 2018-10-18 | タリックス ファーマシューティカルズ リミテッド | 表皮水疱症の処置のための方法及び組成物 |
| CA3076610A1 (en) * | 2017-09-22 | 2019-03-28 | University Of Miami | Methods and compositions for the treatment of epidermolysis bullosa |
-
2022
- 2022-08-11 CA CA3228644A patent/CA3228644A1/en active Pending
- 2022-08-11 JP JP2024508686A patent/JP2024531238A/ja active Pending
- 2022-08-11 MX MX2024001935A patent/MX2024001935A/es unknown
- 2022-08-11 WO PCT/US2022/040092 patent/WO2023018891A1/en not_active Ceased
- 2022-08-11 AU AU2022326485A patent/AU2022326485A1/en active Pending
- 2022-08-11 IL IL310759A patent/IL310759A/en unknown
- 2022-08-11 GB GB2402730.2A patent/GB2628229A/en active Pending
- 2022-08-11 EP EP22856622.0A patent/EP4384498A1/en active Pending
- 2022-08-11 CN CN202280068270.9A patent/CN118076583A/zh active Pending
-
2024
- 2024-02-09 US US18/437,793 patent/US20240299326A1/en active Pending
- 2024-03-06 CO CONC2024/0002786A patent/CO2024002786A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023018891A1 (en) | 2023-02-16 |
| US20240299326A1 (en) | 2024-09-12 |
| GB2628229A (en) | 2024-09-18 |
| AU2022326485A1 (en) | 2024-02-29 |
| CO2024002786A2 (es) | 2024-03-18 |
| GB202402730D0 (en) | 2024-04-10 |
| CA3228644A1 (en) | 2023-02-16 |
| CN118076583A (zh) | 2024-05-24 |
| WO2023018891A8 (en) | 2023-09-21 |
| IL310759A (en) | 2024-04-01 |
| JP2024531238A (ja) | 2024-08-29 |
| EP4384498A1 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001204A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con derivados de aceite de pescado para usarse en tratar enfermedades del higado graso. | |
| BR112022011951A2 (pt) | Tratamento de esclerose lateral amiotrófica e distúrbios relacionados | |
| EP4491229A3 (en) | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| EP4541422A3 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| EP4353317A3 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MX388579B (es) | Combinacion de un compuesto de cromeno y un segundo agente activo. | |
| MX2024001935A (es) | Metodos y composiciones para tratar el cancer. | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| HK1232227A1 (zh) | 作为pi3k抑制剂的喹嗪酮衍生物 | |
| MX2023011176A (es) | Tratamiento de hidradenitis supurativa con orismilast. | |
| EP4578499A3 (en) | Resmetirom for reducing liver volume | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| MX2025013372A (es) | Inhibidores de gsk3\03b1 y metodos de uso de estos | |
| WO2021231931A8 (en) | Methods of treating sars-cov-2 infections | |
| WO2020092127A8 (en) | Novel sting agonists | |
| AU2019296118A8 (en) | Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor | |
| BR112022020283A2 (pt) | Agente para tratamento de lesão renal aguda induzida por contraste | |
| MY207796A (en) | Thiophene derivatives as xanthine oxidase inhibitors and application thereof | |
| MX2021006121A (es) | Profarmaco de gemcitabina oralmente activo. | |
| BR112022001809A2 (pt) | Agente terapêutico e método para tratar câncer resistente ao anticorpo anti-ccr4, composto, e, uso de um composto | |
| AU2020326552A8 (en) | Pyrimidine-5-carboxamide compound | |
| BR112021024835A2 (pt) | Tratamento para sinuclenopatias | |
| MX2021009188A (es) | Uso de composición que contiene inhibidor de quinasa dependiente de ciclina 4/6 en combinación con anastrozol en la preparación de medicamentos para el tratamiento de enfermedades tumorales. |